Bristol-based DeepTech company Astral Systems has raised €26 million (£23 million) in Series A funding to accelerate the commercial deployment of its multi-state fusion (MSF) technology, with a focus on producing critical medical isotopes for healthcare and research applications.
The round was led by Mercia Ventures, with participation from Tees River, Daphni, Blast Club, and existing investors including Speedinvest and Playfair. The funding brings the company’s total capital raised to more than €32 million (£28 million).
Fusion Technology for Near-Term Medical Use
Astral Systems is developing a novel form of fusion technology known as multi-state fusion (MSF), which the company claims can enable compact, modular reactors capable of generating high-intensity neutron flux.
While fusion energy remains a long-term ambition, Astral is prioritizing a nearer-term commercial application: the production of medical isotopes used in diagnostics, cancer treatment, and biomedical research.
The company aims to bring isotope production capabilities to market by early 2027.
Addressing a Fragile Global Isotope Supply Chain
Medical isotopes are essential in more than 50 million nuclear medicine procedures annually worldwide, but global supply chains remain limited and vulnerable to disruption.
Astral Systems positions its technology as a solution to this bottleneck by enabling on-demand, localized isotope production through compact fusion reactors.
The company believes this approach could reduce dependency on aging nuclear infrastructure and international supply chains while improving access to critical medical materials.
Scaling Modular Fusion Reactors
With the new funding, Astral plans to:
- Scale production of its modular MSF reactor systems
- Expand operations at its facility at the former Berkeley Power Station
- Run multiple next-generation fusion reactors at full capacity by the end of 2026
- Advance commercial deployment of isotope production systems
The company is also targeting the development of what it describes as the highest-flux private neutron source in the world, intended for both medical and industrial applications.
Early Commercial Traction
Despite being a DeepTech fusion company, Astral Systems has already generated revenue through research contracts, reporting more than €3.4 million (£3 million) in earnings.
The company operates three commercial fusion facilities and collaborates with institutions such as McMaster Universityand Brazil’s Institute for Energy and Nuclear Research (IPEN) on isotope development projects.
Key isotopes under development include Actinium-225 and Lead-212, both considered highly valuable for next-generation cancer therapies.
Expanding Team and Research Capabilities
Astral Systems is also scaling its workforce, planning to grow from 23 to over 40 employees by the end of 2026.
Recent hires include senior scientific leadership such as NASA Laureate and nuclear physicist Dr. Theresa Benyo, appointed as Chief Research Officer.
The company is also conducting advanced research into nuclear fuel cycles and tritium breeder blanket systems in collaboration with the University of Bristol, supported by UK government funding initiatives.
From Fusion Energy to Medical Infrastructure
While fusion energy remains part of its long-term vision, Astral Systems is positioning itself primarily as a medical isotope infrastructure company in the near term.
This dual-use approach places the company at the intersection of energy innovation, nuclear science, and healthcare supply chains.
Building a New Nuclear-Enabled Health Supply Chain
If successful, Astral’s technology could help establish a more resilient and decentralized supply of medical isotopes, reducing global shortages that impact cancer diagnosis and treatment.
The company’s approach reflects a broader trend in DeepTech: leveraging advanced physics and energy systems to solve urgent healthcare and industrial challenges.
With new funding secured, Astral Systems is now accelerating toward commercialization, aiming to make fusion-enabled isotope production a viable component of modern medical infrastructure within the next few years.
